10-Q: Kairos Pharma Amends Executive Employment Agreements, Secures $30 Million Equity Line of Credit and Reports Q3 2024 Results

Kairos Pharma amends executive employment agreements, secures a $30 million equity line of credit, and reports a net loss of $1.623 million for the nine months ended September 30, 2024, while also detailing various financial and operational updates.

Summary

• Kairos Pharma has amended employment agreements with its executive officers, delaying the start of their base salaries and annual RSU grants to January 1, 2025.
• The company secured a $30 million equity line of credit with Helena Global Investment Opportunities I LTD, which will become available upon filing a registration statement.
• Kairos reported a net loss of $1.623 million for the nine months ended September 30, 2024, and a net loss of $1.047 million for the three months ended September 30, 2024.
• The company's cash balance was $3.217 million as of September 30, 2024, and they expect this to last at least 12 months from the filing date.
• Kairos completed its IPO on September 16, 2024, raising $5.524 million in net proceeds.
• The company converted convertible notes payable and certain accounts payable into common stock upon the closing of the IPO.
• Research and development expenses increased to $242,000 for the nine months ended September 30, 2024, due to the start of a Phase 2 clinical trial.
• The company entered into several agreements for clinical research, bioassay services, and advisory services, with advance payments totaling $1.815 million.
• Kairos has ongoing license agreements with Cedars-Sinai Medical Center, with amendments made to address outstanding liabilities.
• The company has an agreement with Cross Current Capital LLC for consulting services, involving a $200,000 cash payment and $500,000 in restricted shares.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has secured funding and is progressing with clinical trials, the significant net losses and reliance on future capital raises temper the positive aspects. The delay in executive compensation also adds a note of caution.

Positives

• The company successfully completed its IPO, raising $5.524 million in net proceeds.
• Kairos secured a $30 million equity line of credit, providing potential future funding.
• The company expects its current cash balance to last at least 12 months.
• The company is actively progressing its clinical trials, as evidenced by increased R&D expenses.
• The company has addressed outstanding liabilities with Cedars-Sinai through conversion agreements.

Negatives

• The company reported a significant net loss of $1.623 million for the nine months ended September 30, 2024.
• The company has incurred significant operating losses since inception.
• The company is reliant on additional funding to continue operations.
• The company has made substantial advance payments for services, which may impact short-term cash flow.
• The company's disclosure controls and procedures were deemed not effective at a reasonable assurance level as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on attaining and maintaining profitable operations and raising additional capital.
• There is no assurance that future financing will be available or on satisfactory terms.
• The company may face significant expenses related to commercialization if its product candidates are approved.
• The company's product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator.
• The company's disclosure controls and procedures were not effective at a reasonable assurance level as of September 30, 2024.

Future Outlook

The company expects its current cash balance to last at least 12 months and will require additional funding to complete clinical development and commercialize its product candidates. They plan to finance future operations through a combination of equity and debt financings, collaborations, strategic alliances, and licensing arrangements.

Management Comments

• Management expects the current cash balance to last at least 12 months from the filing date.
• Management acknowledges the need for additional funding to support ongoing operations and growth strategy.
• Management believes that the company's patents and underlying technology have continuing value, although the amount of future benefits is uncertain.

Industry Context

This announcement reflects the typical financial challenges faced by early-stage biotechnology companies, which often rely on equity and debt financing to fund research and development. The company's focus on immunotherapy and cell therapy aligns with current trends in oncology treatment. The securing of an equity line of credit is a common strategy for biotech companies to ensure access to capital.

Comparison to Industry Standards

• The reported net losses are typical for a clinical-stage biotech company that has not yet generated revenue from product sales. Companies like Xencor and Iovance Biotherapeutics, which are also in the clinical stage of development, often report similar losses.
• The cash runway of 12 months is a common benchmark for biotech companies, and the company's ability to secure an equity line of credit is a positive step in ensuring continued operations. Companies like Adaptimmune and Gritstone bio also utilize similar financing strategies.
• The increase in R&D expenses is consistent with the progression of clinical trials, which is a key indicator of progress in the biotech industry. Companies like BioNTech and Moderna have also shown significant increases in R&D spending as they advanced their clinical programs.
• The conversion of debt and payables into equity is a common practice for early-stage companies to reduce liabilities and strengthen their balance sheet. This is similar to strategies used by companies like Cellectis and bluebird bio in their early stages.

Related Party Transactions

• The company entered into note payable agreements with three of its officers totaling $142,000.
• The company converted amounts due to related parties into common stock upon the closing of the IPO.
• The company has an agreement with its former Chief Financial Officer that requires the company to pay $50 upon the completion of raising more than $850 in debt or equity financing.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees will have their base salaries and RSU grants delayed until January 1, 2025.
• Customers (potential patients) may benefit from the company's continued development of new therapies.
• Suppliers and creditors may be impacted by the company's financial performance and payment schedules.

Next Steps

• The company will file a registration statement on Form S-1 to make the equity line of credit available.
• The company will continue to advance its clinical trials for ENV-105 and KROS-201.
• The company will continue to seek additional funding through various means.
• The company will continue to work with Cedars-Sinai to resolve outstanding liabilities.
• The company will continue to develop and submit a companion diagnostic to the FDA.

Key Dates

Keywords

biotechnology, pharmaceutical, immunotherapy, cell therapy, oncology, clinical trials, IPO, equity line of credit, restricted stock units, licensing agreements